Applied DNA Sciences, Inc. (NASDAQ:APDN) Short Interest Down 36.4% in April

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 471,800 shares, a decline of 36.4% from the March 31st total of 741,500 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is presently 0.4 days. Approximately 7.8% of the company’s stock are short sold.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in Applied DNA Sciences during the fourth quarter worth about $28,000. Connective Capital Management LLC bought a new stake in shares of Applied DNA Sciences in the 4th quarter worth approximately $36,000. Jane Street Group LLC bought a new stake in shares of Applied DNA Sciences in the 3rd quarter worth approximately $48,000. Finally, Geode Capital Management LLC boosted its position in Applied DNA Sciences by 291.1% during the 4th quarter. Geode Capital Management LLC now owns 417,485 shares of the technology company’s stock valued at $85,000 after purchasing an additional 310,749 shares during the period. 22.22% of the stock is currently owned by institutional investors.

Applied DNA Sciences Stock Up 1.7 %

Shares of NASDAQ APDN opened at $0.86 on Tuesday. The stock’s 50 day moving average price is $3.05 and its two-hundred day moving average price is $7.63. Applied DNA Sciences has a 52-week low of $0.72 and a 52-week high of $237.50. The stock has a market capitalization of $951,206.40, a P/E ratio of -0.15 and a beta of 0.86.

Applied DNA Sciences (NASDAQ:APDN) last posted its quarterly earnings results on Thursday, February 13th. The technology company reported ($28.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($16.00) by ($12.00). Applied DNA Sciences had a negative net margin of 228.12% and a negative return on equity of 101.57%. On average, analysts anticipate that Applied DNA Sciences will post -0.87 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Applied DNA Sciences in a research note on Monday, March 17th. They set a “sell” rating on the stock.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.